Veracyte Biopharma Services

Earlier this week at the American Association for Cancer Research 2024 Annual Meeting, Veracyte took center stage by hosting a Spotlight Theater, highlighting our key role as an experienced partner in all phases of drug development - from biomarker discovery to diagnostics. Additionally, Veracyte, in collaboration with Kite Pharma, a Gilead company, presented a groundbreaking poster demonstrating the power of Veracyte's Brightplex® assay to understand the dynamic changes within the tumor microenvironment and their impact on treatment outcomes for patients with large B-cell lymphoma undergoing axillary cell therapy. 🔗 Access to the poster here: https://lnkd.in/ewaB8Vt8 #AACR24 #oncology

Stop by our #AACR24 poster session today from 1:30- 5:00 p.m. PT: “Dynamic Changes in the Tumor Microenvironment from Initial Diagnosis through Sequential Therapies in Patients with Large B Cell Lymphoma Undergoing Axicabtagene Ciloleucel (Axi-cel) Treatment.” with our partner Kite Pharma, a Gilead company, demonstrating the utility of Brightplex® assays. Meet Aurélie Auguste, PhD, Director Translational Data Analysis, Biopharma at Veracyte, presenting this poster. Download our poster: https://lnkd.in/e9KQcaQh

Meet our team at the American Association for Cancer Research Annual Meeting, in San Diego (booth 623) as we showcase our cutting-edge services designed to meet our partners’ global needs for their drug development programs, from biomarker discovery to diagnostic applications. #AACR24 #oncology https://lnkd.in/eKkFjGDp

Today at the American Association for Cancer Research 2024 Annual Meeting: Join us in Theater B, at 3-4 p.m. PT, for “Advancing Precision Medicine: From Biomarker Discovery to Diagnostics and Minimal Residual Disease." Learn about Veracyte’s latest capabilities, including our new MRD platform, and how they are improving clinical trial assays and IVD development. 🔗 Register here: https://lnkd.in/ecmfePBM. #AACR24 #oncology

There is still one day left to register for Veracyte's Spotlight Theater at #AACR24, "Advancing Precision Medicine: From Biomarker Discovery to Diagnostics and Minimal Residual Disease," on Monday, April 8, 3-4 p.m. PT, Theater B. Reserve your seat: https://lnkd.in/ecmfePBM

Meet our team at the American Association for Cancer Research Annual Meeting, in San Diego (booth 623) as we showcase our cutting-edge services designed to meet our partners’ global needs for their drug development programs, from biomarker discovery to diagnostic applications. #AACR24 #oncology https://lnkd.in/eKkFjGDp

Join us at the American Association for Cancer Research Annual Meeting, in San Diego, April 5-10. Make sure to visit our poster "Dynamic Changes in the Tumor Microenvironment from Initial Diagnosis through Sequential Therapies in Patients with Large B Cell Lymphoma Undergoing Axicabtagene Ciloleucel (Axi-cel) Treatment", with our partner Kite Pharma, a Gilead company, demonstrating the utility of Brightplex® assays, presented by @Aurelie Auguste, PhD, Director Translational Data Analysis, Biopharma at Veracyte on Tuesday April 9, 2024 1:30- 5:00 p.m. PT (Poster Section 51, Board Number: 20). Our Biopharma Services team is looking forward to meeting you there. See you at booth #623 #AACR24 #oncology https://lnkd.in/eKkFjGDp

Veracyte at the American Association for Cancer Research Annual Meeting, in San Diego, April 5-10. Book your seat for our Spotlight Theater. The session titled "Advancing Precision Medicine: From Biomarker Discovery to Diagnostics and Minimal Residual Disease" will be held on Monday, April 8, 3-4 p.m. PT, Theater B and will explore Veracyte's latest capabilities, including our new MRD platform, and how these innovations can be leveraged for clinical trial assays and gain insights into our comprehensive IVD development capabilities. Our Biopharma Services team is looking forward to meeting you there. See you at booth #623 #AACR24 #oncology Book your seat for our Spotlight Theater: https://lnkd.in/ecmfePBM

Join us at the American Association for Cancer Research Annual Meeting, in San Diego, April 5-10, to learn more about how Veracyte's Biopharma Services can help support our partners’ drug development programs. Our Biopharma Services team is looking forward to meeting you there. See you at booth 623. #AACR24 #oncology https://lnkd.in/eKkFjGDp

📢 Didn't attend our recent Xtalks webinar on Veracyte's Immunoscore IC® (CD8/PDL1)? No worries! The Veracyte Biopharma Services team welcomes you to watch the replay! hashtag#Immunotherapy has made remarkable progress in recent years, revolutionizing the way we fight hashtag#cancer. The identification and use of biomarkers that allow clinicians to tailor treatments to individual patients are key factors. In this session, the Immunoscore® Immune Checkpoint (CD8/PDL1) assay is showcased with an in-depth review of the assay's analytical performance, clinical relevance, and efficacy with a focus on metastatic colorectal cancer (#mCRC) and non-small cell lung cancer (#NSCLC). #DrugDevelopment #Innovation #XtalksWebinar 🎥 Click here to get access: https://lnkd.in/eQKACCAF